AX9 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginA gross margin near 79% indicates Vafseo generates substantial product-level economics before operating expenses. That provides room to support commercialization, absorb reimbursement deductions, and potentially improve profitability as the business scales, although operating losses remain.
Positive Cash GenerationPositive operating and free cash flow mark a significant improvement from negative cash generation during 2021–2024. This gives Akebia greater internal funding capacity for commercialization and development, while reducing immediate reliance on external capital to sustain operations.
VOICE Trial AdvantageThe favorable interim VOICE outcome may strengthen Vafseo’s clinical and competitive positioning in CKD anemia, particularly through the reported reduction in hospitalizations. Early trial success can support adoption and improve the durability of the marketed product franchise.
Bears Say
Persistent Operating LossesAkebia has not yet converted strong product-level gross profitability into consistent company-wide earnings. The return to negative EBIT and EBITDA, combined with recent revenue contraction, could constrain reinvestment and weaken the sustainability of its commercial growth.
Fragile Balance SheetDebt materially exceeds equity and the history of negative equity shows meaningful capital strain. Although leverage improved from 2025, this balance-sheet profile leaves less flexibility to fund development, absorb execution setbacks, or support commercialization without additional financing.
Unstable Free Cash FlowPositive free cash flow is encouraging, but the sharp year-over-year decline indicates that cash generation is not yet dependable. Continued variability could reduce the resources available for product investment and increase sensitivity to operating performance or financing needs.
Akebia Therapeutics News
AX9 FAQ
What was Akebia Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Akebia Therapeutics’s market cap?
Akebia Therapeutics’s market cap is CHF202.58M.
When is Akebia Therapeutics’s upcoming earnings report date?
Akebia Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 21 days.
How were Akebia Therapeutics’s earnings last quarter?
Akebia Therapeutics released its earnings results on Aug 05, 2026. The company reported -CHF0.025 earnings per share for the quarter, beating the consensus estimate of -CHF0.035 by CHF0.01.
Is Akebia Therapeutics overvalued?
According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued.
Does Akebia Therapeutics pay dividends?
Akebia Therapeutics does not currently pay dividends.
What is Akebia Therapeutics’s EPS estimate?
Akebia Therapeutics’s EPS estimate is -0.03.
How many shares outstanding does Akebia Therapeutics have?
Akebia Therapeutics has 277,106,230 shares outstanding.
What happened to Akebia Therapeutics’s price movement after its last earnings report?
Akebia Therapeutics reported an EPS of -CHF0.025 in its last earnings report, beating expectations of -CHF0.035. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Akebia Therapeutics?
Currently, no hedge funds are holding shares in CH:AX9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Akebia Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF3.24 (― Upside)
CHF3.24 (― Upside)
Blogger Sentiment
Bullish
CH:AX9 Sentiment 75%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.40%
12-Months-Change
Fundamentals
Return on Equity
-93.74%
Trailing 12-Months
Asset Growth
1.18%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Akebia Therapeutics
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
AX9 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights strong commercial momentum for Vafseo (32% revenue growth, ~60% patient growth quarter-over-quarter, higher prescriber engagement and improved adherence under observed dosing) and meaningful pipeline progress with supportive clinical data and upcoming readouts. However, legacy product Auryxia faces notable generic-driven revenue decline (≈-17%), the company swung to a net loss in the quarter, experienced sizable inventory write-downs and higher operating expenses, and cash declined q/q. While the launch and clinical developments are encouraging and provide a clear growth narrative, the near-term financial headwinds and competitive/enrollment risks temper the outlook.View all CH:AX9 earnings summaries